Search

Search Constraints

You searched for: Author/Creator Dalle, Stephane

Search Results

3. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. (September 2022)

4. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Issue 11 (November 2020)

5. Alarms and Parameters Generated by Hematology Analyzer: New Tools to Predict and Quantify Circulating Sezary Cells. Issue 2 (20th March 2014)

6. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Issue 10094 (5th August 2017)

7. Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T‐cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop. (2nd May 2022)

8. Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T‐cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop. (1st May 2022)

10. Double-hit and dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas. (2019)